{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:32:20Z","timestamp":1790699540197,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:27:34Z","timestamp":1736814454000},"page":"449-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spot Urine Protein\/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Saad","family":"Jamshed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ammad-Ud-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Celotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9083-4219","authenticated-orcid":false,"given":"Irfan Ul Haq","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2025.01.003_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.01.003_bib0002","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.01.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.01.003_bib0004","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.clml.2025.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1373\/clinchem.2008.106153","article-title":"Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population","volume":"54","author":"Piehler","year":"2008","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.clml.2025.01.003_bib0006","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2014.333","article-title":"The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease","volume":"87","author":"Yadav","year":"2015","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.clml.2025.01.003_bib0007","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.01.003_bib0008","doi-asserted-by":"crossref","first-page":"e20042","DOI":"10.1200\/JCO.2018.36.15_suppl.e20042","article-title":"Correlation between 24-hour urine protein and spot urine protein-to-creatinine ratio in multiple myeloma","volume":"36","author":"Jamshed","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.01.003_bib0009","first-page":"443","article-title":"Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria","volume":"20","author":"Wahbeh","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"3","key":"10.1016\/j.clml.2025.01.003_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1440-1797.2006.00564.x","article-title":"Can spot urine protein\/creatinine ratio replace 24 h urine protein in usual clinical nephrology?","volume":"11","author":"Lane","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"10.1016\/j.clml.2025.01.003_bib0011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/rheumatology\/kel360","article-title":"Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis","volume":"46","author":"Leung","year":"2007","journal-title":"Rheumatol (Oxford)"},{"issue":"9","key":"10.1016\/j.clml.2025.01.003_bib0012","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/acr.22828","article-title":"Utility of urinary protein-creatinine ratio and protein content in a 24-hour urine collection in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"68","author":"Medina-Rosas","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.clml.2025.01.003_bib0013","first-page":"419","article-title":"The spot urine protein\/creatinine ratio is a simple, rapid and inexpensive method for monitoring patients with light-chain multiple myeloma","volume":"3","author":"Cooper","year":"2010","journal-title":"NDT Plus"},{"key":"10.1016\/j.clml.2025.01.003_bib0014","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2015.07.541","article-title":"Use of protein-to-creatinine ratio in spot urine samples for the evaluation of proteinuria in patients with multiple myeloma","volume":"15","author":"Le Mouel","year":"2015","journal-title":"Clin Lymph Myeloma Leuke"},{"issue":"5","key":"10.1016\/j.clml.2025.01.003_bib0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ajcp\/93.5.689","article-title":"The optimum urine collections for the detection and monitoring of Bence Jones proteinuria","volume":"93","author":"Brigden","year":"1990","journal-title":"Am J Clin Pathol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.003_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2024-199615","article-title":"24-Hour urine testing does not add value to multiple myeloma response assessments: a secondary analysis of BMT CTN 0702","volume":"144","author":"Banerjee","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:26:09Z","timestamp":1747686369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502500014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S215226502500014X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spot Urine Protein\/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}